At the news
? NEUTRALIMPACT 2/10 8-K filed Aug 24, 2026 at 07:01 ET
ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the resignation of director Muthusamy Shanmugam, who remains in his executive management role. The board changes are routine and carry no material financial impact on the company's operations or outlook.
- Henry Gosebruch appointed to the Board of Directors effective August 19, 2026
- Muthusamy Shanmugam resigned as director effective August 23, 2026, but remains Head of R&D and COO of NJ Operations
- Gosebruch receives an initial restricted stock award with a grant date fair value of $525,000, vesting over three years
- Gosebruch brings over 30 years of biopharma strategy and M&A experience, including former EVP and Chief Strategy Officer at AbbVie
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access